Global Eylea Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Eylea Market Research Report 2024
EYLEA® (aflibercept) Injection 2 mg (0.05mL) is a prescription medicine approved for the treatment of patients with Wet Age-related Macular Degeneration (AMD).
According to Mr Accuracy reports new survey, global Eylea market is projected to reach US$ 7305.9 million in 2029, increasing from US$ 5617 million in 2022, with the CAGR of 3.8% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Eylea market research.
The Eylea market is primarily driven by the increasing prevalence of retinal diseases and the demand for effective treatments. Eylea (aflibercept) is a medication used to treat various eye conditions, including wet age-related macular degeneration (AMD) and diabetic macular edema. The growing aging population and the rise in chronic diseases like diabetes contribute to market growth. Moreover, advancements in ocular therapeutics and the demonstrated efficacy of Eylea in improving visual outcomes further propel adoption. However, challenges include managing the high cost of treatment and ensuring equitable access to care. Navigating the competitive landscape, optimizing treatment protocols, and addressing potential side effects are ongoing concerns. The market's success relies on continuous research to expand the indications for Eylea, collaborations between pharmaceutical manufacturers and ophthalmologists, and comprehensive patient education on the benefits and potential risks of treatment while addressing the evolving challenges associated with retinal disease management and treatment affordability.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Eylea market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Regeneron
Bayer
Segment by Type
Prefilled Syring Package
Vial Package
Hospital
Retail Pharmacy
Other
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Eylea report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Eylea market is projected to reach US$ 7305.9 million in 2029, increasing from US$ 5617 million in 2022, with the CAGR of 3.8% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Eylea market research.
The Eylea market is primarily driven by the increasing prevalence of retinal diseases and the demand for effective treatments. Eylea (aflibercept) is a medication used to treat various eye conditions, including wet age-related macular degeneration (AMD) and diabetic macular edema. The growing aging population and the rise in chronic diseases like diabetes contribute to market growth. Moreover, advancements in ocular therapeutics and the demonstrated efficacy of Eylea in improving visual outcomes further propel adoption. However, challenges include managing the high cost of treatment and ensuring equitable access to care. Navigating the competitive landscape, optimizing treatment protocols, and addressing potential side effects are ongoing concerns. The market's success relies on continuous research to expand the indications for Eylea, collaborations between pharmaceutical manufacturers and ophthalmologists, and comprehensive patient education on the benefits and potential risks of treatment while addressing the evolving challenges associated with retinal disease management and treatment affordability.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Eylea market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Regeneron
Bayer
Segment by Type
Prefilled Syring Package
Vial Package
Segment by Application
Hospital
Retail Pharmacy
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Eylea report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices